1. Home
  2. ABEO vs NNNN Comparison

ABEO vs NNNN Comparison

Compare ABEO & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Abeona Therapeutics Inc.

ABEO

Abeona Therapeutics Inc.

N/A

Current Price

$5.42

Market Cap

399.5M

Sector

Health Care

ML Signal

N/A

Logo Anbio Biotechnology Class A Ordinary Shares

NNNN

Anbio Biotechnology Class A Ordinary Shares

N/A

Current Price

$6.34

Market Cap

340.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ABEO
NNNN
Founded
1974
2021
Country
United States
Germany
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
399.5M
340.2M
IPO Year
2005
2023

Fundamental Metrics

Financial Performance
Metric
ABEO
NNNN
Price
$5.42
$6.34
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$20.00
N/A
AVG Volume (30 Days)
1.5M
222.7K
Earning Date
05-13-2026
04-07-2026
Dividend Yield
N/A
N/A
EPS Growth
165.16
N/A
EPS
N/A
N/A
Revenue
$2,998,000.00
N/A
Revenue This Year
$1,024.31
N/A
Revenue Next Year
$145.42
N/A
P/E Ratio
N/A
$446.57
Revenue Growth
258.18
N/A
52 Week Low
$4.00
$6.13
52 Week High
$7.65
$51.33

Technical Indicators

Market Signals
Indicator
ABEO
NNNN
Relative Strength Index (RSI) 34.08 29.63
Support Level $4.91 N/A
Resistance Level $5.52 $13.46
Average True Range (ATR) 0.20 0.72
MACD -0.04 0.04
Stochastic Oscillator 19.31 13.33

Price Performance

Historical Comparison
ABEO
NNNN

About ABEO Abeona Therapeutics Inc.

Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.

About NNNN Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).

Share on Social Networks: